High-dose baclofen for the treatment of alcohol dependence (BACLAD study): A randomized, placebo-controlled trial

European Neuropsychopharmacology

Volumn 25, Issue 8, 2015, Pages 1167-1177

  Müller, Christian A ^a   Geisel, Olga ^a   Pelz, Patricia ^a   Higl, Verena ^a   Krüger, Josephine ^a   Stickel, Anna ^a   Beck, Anne ^a   Wernecke, Klaus Dieter ^a   Hellweg, Rainer ^a   Heinz, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BACLOFEN; GAMMA GLUTAMYLTRANSFERASE; PLACEBO; DRUGS USED IN THE TREATMENT OF ADDICTION;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMMON COLD; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV-TR; FASCICULATION; FATIGUE; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HAMILTON ANXIETY SCALE; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MEAN CORPUSCULAR VOLUME; MEDICATION COMPLIANCE; MIDDLE AGED; MUSCLE WEAKNESS; MYALGIA; PAIN; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TINGLING; SLEEP DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; VERTIGO; VISUAL ANALOG SCALE; VISUAL DISORDER; KAPLAN MEIER METHOD; PSYCHOLOGY;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL DETERRENTS; ALCOHOLISM; BACLOFEN; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84938745791     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.04.002     Document Type: Article

References (51)

1. American Psychiatric Association (APA) Diagnostic and Statistical Manual of Mental Disorders 2000, fourth ed., text revision (DSM-IV-TR), American Psychiatric Association, Washington, DC.
2. Addolorato G., Caputo F., Capristo E., et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002, 37:504-508.
3. Addolorato G., Leggio L., Ferrulli A., et al. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol 2011, 46:312-317.
4. Addolorato G., Leggio L., Ferrulli A., et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007, 370:1915-1922.
5. Agabio R., Colombo G. GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence. Front. Neurosci. 2014, 8:140.
6. Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol 2005, 40:147-150.
7. Agence nationale de sécurité du médicament et des produits de santé (ANSM), Recommandation Temporaire d'Utilisation (RTU) du baclofène dans le traitement de l'alcoolo-dépendance, 2014, available from: 〈〉. [22.01.2015]. http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Une-recommandation-temporaire-d-utilisation-RTU-est-accordee-pour-le-baclofene-Point-d-information.
8. Anton R.F., Moak D.H., Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin. Exp. Res. 1995, 19:1992-1999.
9. Anton R.F., O'Malley S.S., Ciraulo D.A., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. J. Am. Med. Assoc. 2006, 295:2003-2017.
10. Beck A., Wüstenberg T., Genauck A., et al. Effect of brain structure, brain function, and brain connectivity on relapse in alcohol-dependent patients. Arch. Gen. Psychiatry 2012, 69:842-852.
11. Boothby L.A., Doering P.L. Acamprosate for the treatment of alcohol dependence. Clin. Ther. 2005, 27:695-714.
12. Bottlender M., Spanagel R., Soyka M. [One drink, one drunk--controlled drinking by alcoholics? 3-year-outcome after intensive outpatient treatment]. Psychoth. Psychosom. Med. Psychol. 2007, 57:32-38.
13. Bowery N.G., Hudson A.L., Price G.W. GABAA and GABAB receptor site distribution in the rat central nervous system. Neuroscience 1987, 20:365-383.
14. Brunner E., Domhof S., Langer F. Nonparametric Analysis of Longitudinal Data in Factorial Experiments 2002, Wiley & Sons, New York.
15. Caputo F., Vignoli T., Grignaschi A., Cibin M., Addolorato G., Bernardi M. Pharmacological management of alcohol dependence: from mono-therapy to pharmacogenetics and beyond. Eur. Neuropsychopharmacol. 2014, 24:181-191.
16. Colombo G., Addolorato G., Agabio R., et al. Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotox. Res. 2004, 6:403-414.
17. Colombo G., Vacca G., Serra S., Brunetti G., Carai M.A., Gessa G.L. Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology (Berl) 2003, 167:221-224.
18. de Beaurepaire R. Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients. Front. Psychiatry 2012, 3:103.
19. Di Chiara G., Bassareo V. Reward system and addiction: what dopamine does and doesn't do. Curr. Opin. Pharmacol. 2007, 7:69-76.
20. European Medicines Agency (EMA), 2013, available from: 〈〉. [22.01.2015]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002583/human_med_001620.jsp&mid=WC0b01ac058001d124.
21. Evans S.M., Bisaga A. Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcohol Clin. Exp. Res. 2009, 33:19-30.
22. Fadda P., Scherma M., Fresu A., Collu M., Fratta W. Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 2003, 50:1-6.
23. Franchitto N., Pelissier F., Lauque D., Simon N., Lancon C. Self-intoxication with baclofen in alcohol-dependent patients with co-existing psychiatric illness: an emergency department case series. Alcohol Alcohol 2014, 49:79-83.
24. Garbutt J.C., Kampov-Polevoy A.B., Gallop R., Kalka-Juhl L., Flannery B.A. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin. Exp. Res. 2010, 34:1849-1857.
25. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
26. Hamilton M. HAMA-Hamilton Anxiety Scale 1976, National Institute of Mental Health, Rockville, MD.
27. Harris R.A., Trudell J.R., Mihic S.J. Ethanol's molecular targets. Sci. Signal. 2008, 1:re7.
28. Heinz A. Dopaminergic dysfunction in alcoholism and schizophrenia--psychopathological and behavioral correlates. Eur, Psychiatry 2002, 17:9-16.
29. Johnson B.A., Rosenthal N., Capece J.A., et al. Topiramate for treating alcohol dependence: a randomized controlled trial. J. Am. Med. Assoc. 2007, 298:1641-1651.
30. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35:217-238.
31. Mann K., Ackermann K. Die OCDS-G: Psychometrische Kennwerte der deutschen Version der Obsessive Compulsive Drinking Scale. Sucht 2000, 24:90-100.
32. Mann K., Bladstrom A., Torup L., Gual A., van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol. Psychiatry 2013, 73:706-713.
33. Maurer W., Hothorn L., Lehmacher W. Multiple Comparisons in Drug Clinical Trials and Preclinical Assays: A-priori Ordered Hypotheses 1995, vol. 6. Fischer, Stuttgart.
34. Mottola C.A. Measurement strategies: the visual analogue scale. Decubitus 1993, 6:56-58.
35. Müller C.A., Geisel O., Banas R., Heinz A. Current pharmacological treatment approaches for alcohol dependence. Expert Opin. pharmacotherapy 2014, 15:471-481.
36. Müller C.A., Schafer M., Schneider S., et al. Efficacy and safety of levetiracetam for outpatient alcohol detoxification. Pharmacopsychiatry 2010, 43:184-189.
37. Pastor A., Jones D.M., Currie J. High-dose baclofen for treatment-resistant alcohol dependence. J. Clin. Psychopharmacol. 2012, 32:266-268.
38. Pettinati H.M., Weiss R.D., Miller W.R., Donovan D., Ernst D.B., Rounsaville B.J. Medical Management Treatment Manual 2004, National Institute on Alcohol Abuse and Alcoholism, Bethesda.
39. Rolland B., Bordet R., Deheul S., Cottencin O. Baclofen for alcohol-dependence: anticraving or partial substitution?. J. Clin. Psychopharmacol. 2013, 33:280-281.
40. Rösner S., Hackl-Herrwerth A., Leucht S., Lehert P., Vecchi S., Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010, CD004332.
41. Rösner S., Hackl-Herrwerth A., Leucht S., Vecchi S., Srisurapanont M., Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst. Rev. 2010, CD001867.
42. Sheehan D.V., Lecrubier Y., Sheehan K.H., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):22-33. quiz 34-57.
43. Skinner H.A., Horn J.L. Alcohol Dependence Scale: Users Guide 1984, Addiction Research Foundation, Toronto.
44. Sobell L.C., Sobell M.B. Timeline Follow-back: A Technique for Assessing Self-reported Ethanol Consumption 1992, Humana Press, Totowa, NJ.
45. Spanagel R., Vengeliene V., Jandeleit B, et al. Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacology 2014, 39:783-791.
46. Suh J.J., Pettinati H.M., Kampman K.M., O'Brien C.P. The status of disulfiram: a half of a century later. J. Clin. Psychopharmacol. 2006, 26:290-302.
47. Taira T. Intrathecal administration of GABA agonists in the vegetative state. Prog. Brain Res. 2009, 177:317-328.
48. Westerink B.H., Kwint H.F., deVries J.B. The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J. Neurosci. 1996, 16:2605-2611.
49. Whiteford H.A., Degenhardt L., Rehm J., et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382:1575-1586.
50. World Health Organization (WHO), Internationale Klassifikation psychischer Störungen ICD-10 Kapitel V (F) Forschungskriterien. Dilling H., Mombour W., Schmidt M.H., Schulte-Warkwort E., Eds., 1994, Huber, Bern.
51. Zindel L.R., Kranzler H.R. Pharmacotherapy of alcohol use disorders: seventy-five years of progress. J. Stud. Alcohol Drugs 2014, (Suppl. 75, Suppl, 17):79-88.